PubRank

David Malkin

Author PubWeight™ 109.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012 10.99
2 Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012 6.07
3 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 4.13
4 Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2011 2.53
5 Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006 2.42
6 Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 2013 2.34
7 Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008 2.22
8 Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011 1.85
9 Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 2010 1.81
10 Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008 1.78
11 Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010 1.74
12 A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet 2013 1.66
13 Copy number variations and cancer. Genome Med 2009 1.59
14 Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014 1.56
15 Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003 1.52
16 TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005 1.50
17 Toward a more uniform sampling of human genetic diversity: a survey of worldwide populations by high-density genotyping. Genomics 2010 1.47
18 Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013 1.43
19 De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. Pediatr Blood Cancer 2014 1.39
20 Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007 1.38
21 Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 2004 1.36
22 TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013 1.35
23 Gene expression profiling of childhood adrenocortical tumors. Cancer Res 2007 1.32
24 Floral morphogenesis: stochastic explorations of a gene network epigenetic landscape. PLoS One 2008 1.27
25 Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006 1.25
26 Retracted Copy number variations and cancer susceptibility. Curr Opin Oncol 2010 1.24
27 Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005 1.22
28 A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005 1.11
29 High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum Genet 2007 1.09
30 Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Exp Hematol 2002 1.06
31 The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006 1.06
32 Predictors and mediators of psychological adjustment in mothers of children newly diagnosed with cancer. Psychooncology 2004 1.05
33 Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 2012 1.04
34 Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004 1.03
35 Connecting molecular pathways to hereditary cancer risk syndromes. Am Soc Clin Oncol Educ Book 2013 1.03
36 Neonatal genital herpes simplex virus type 1 infection after Jewish ritual circumcision: modern medicine and religious tradition. Pediatrics 2004 1.03
37 Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer 2006 1.03
38 Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia 2008 1.03
39 Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011 1.02
40 JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009 1.01
41 New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther 2011 0.98
42 Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the hospital for sick children between 1989 and 1999. J Pediatr Hematol Oncol 2004 0.98
43 Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 2006 0.97
44 TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010 0.97
45 Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012 0.96
46 Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008 0.96
47 Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 2008 0.96
48 The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2007 0.95
49 Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol 2014 0.95
50 Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 2013 0.94
51 Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res 2011 0.94
52 A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res 2005 0.93
53 Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 2005 0.92
54 Lymphomatous involvement of the heart in children: two cases and a review of the literature. J Pediatr Hematol Oncol 2004 0.92
55 A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Blood Cancer 2012 0.91
56 Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet Med 2013 0.91
57 A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes. Am J Hum Genet 2010 0.90
58 Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 2011 0.90
59 Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2005 0.87
60 Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 2011 0.86
61 Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs 2006 0.86
62 p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002 0.85
63 Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003 0.84
64 Imaging of cancer predisposition syndromes in children. Radiographics 2011 0.83
65 The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen. Cancer Res 2008 0.83
66 Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle 2009 0.83
67 Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev 2004 0.83
68 Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 2011 0.81
69 Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer 2014 0.81
70 Management of Acute Myeloblastic Leukemia in a Child With Biallelic Mismatch Repair Deficiency. J Pediatr Hematol Oncol 2015 0.81
71 Prenatal diagnosis, preimplantation genetic diagnosis, and cancer: was Hamlet wrong? J Clin Oncol 2009 0.80
72 Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. J Neurooncol 2014 0.79
73 Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol 2014 0.79
74 The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. Cell Cycle 2010 0.79
75 WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2014 0.79
76 Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. Int J Mol Epidemiol Genet 2012 0.79
77 Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. Curr Neurol Neurosci Rep 2012 0.79
78 The cycle of genome-directed medicine. Genome Med 2009 0.78
79 p53 and hereditary cancer. Subcell Biochem 2014 0.78
80 Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp. Pediatr Blood Cancer 2007 0.77
81 Vitamin E: the evidence for multiple roles in cancer. Nutr Cancer 2003 0.77
82 Genetics of childhood cancer. Clin Orthop Relat Res 2002 0.77
83 Cribriform neuroepithelial tumour: novel clinicopathological, ultrastructural and cytogenetic findings. Acta Neuropathol 2011 0.76
84 Health care crisis in Gaza. CMAJ 2009 0.75
85 P53: an old dog begins to learn new tricks. Drug Discov Today 2003 0.75
86 IGF2 is highly expressed in pediatric undifferentiated sarcomas and reveals two distinct cytoplasmic trafficking patterns. Pediatr Dev Pathol 2010 0.75
87 Florid bone marrow haematogones in a child following treatment for acute lymphoblastic leukaemia. Br J Haematol 2006 0.75
88 Postoperative fevers in pediatric solid tumor patients: how should they be managed? J Pediatr Hematol Oncol 2009 0.75
89 Symposium on congenital and acquired bleeding disorders in children (in honor of the lifetime accomplishments of Dr. Victor S. Blanchette in pediatric hematology). Pediatr Blood Cancer 2012 0.75
90 Toxicity and outcome of children with treatment related acute myeloid leukemia. Pediatr Blood Cancer 2008 0.75
91 Unusual ocular presentation of von Hippel-Lindau disease. Can J Ophthalmol 2005 0.75
92 [Infectious complications with herpes virus after ritual Jewish circumcision: a historical and cultural analysis]. Harefuah 2005 0.75
93 Significance of p53 expression in immature teratomas. Pediatr Dev Pathol 2002 0.75
94 Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK? J Pediatr Hematol Oncol 2014 0.75